Historical Valuation
Abrdn Life Sciences Investors (HQL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Abrdn Life Sciences Investors (HQL) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：16.61
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Abrdn Life Sciences Investors (HQL) has a current Price-to-Book (P/B) ratio of 0.75. Compared to its 3-year average P/B ratio of 0.81 , the current P/B ratio is approximately -7.86% higher. Relative to its 5-year average P/B ratio of 0.81, the current P/B ratio is about -7.86% higher. Abrdn Life Sciences Investors (HQL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 0.00%, the current FCF yield is approximately NaN% lower. Relative to its 5-year average FCF yield of 0.00% , the current FCF yield is about NaN% lower.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of HQL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of HQL in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is HQL currently overvalued or undervalued?
Abrdn Life Sciences Investors (HQL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Abrdn Life Sciences Investors (HQL) is between to according to relative valuation methord.
What is Abrdn Life Sciences Investors (HQL) fair value?
HQL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Abrdn Life Sciences Investors (HQL) is between to according to relative valuation methord.
How does HQL's valuation metrics compare to the industry average?
The average P/S ratio for HQL's competitors is , providing a benchmark for relative valuation. Abrdn Life Sciences Investors Corp (HQL) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Abrdn Life Sciences Investors (HQL) as of Jan 18 2026?
As of Jan 18 2026, Abrdn Life Sciences Investors (HQL) has a P/B ratio of 0.75. This indicates that the market values HQL at 0.75 times its book value.
What is the current FCF Yield for Abrdn Life Sciences Investors (HQL) as of Jan 18 2026?
As of Jan 18 2026, Abrdn Life Sciences Investors (HQL) has a FCF Yield of 0.00%. This means that for every dollar of Abrdn Life Sciences Investors’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for Abrdn Life Sciences Investors (HQL) as of Jan 18 2026?
As of Jan 18 2026, Abrdn Life Sciences Investors (HQL) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Abrdn Life Sciences Investors’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Abrdn Life Sciences Investors (HQL) as of Jan 18 2026?
As of Jan 18 2026, Abrdn Life Sciences Investors (HQL) has a Forward P/S ratio of 0.00. This means the market is valuing HQL at $0.00 for every dollar of expected revenue over the next 12 months.